SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
Antivir Ther
; 25(7): 345-347, 2020.
Article
in English
| MEDLINE | ID: covidwho-614744
ABSTRACT
Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question of whether in retrospect we could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Ritonavir
/
Lopinavir
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Antivir Ther
Journal subject:
Drug Therapy
/
Virology
Year:
2020
Document Type:
Article
Affiliation country:
Imp3365
Similar
MEDLINE
...
LILACS
LIS